Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC.
Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Bryan/College Station, TX; and.
J Immunol. 2021 Dec 1;207(11):2856-2867. doi: 10.4049/jimmunol.2100815. Epub 2021 Nov 10.
Complement evasion is a hallmark of extracellular microbial pathogens such as , the causative agent of Lyme disease. Lyme disease spirochetes express nearly a dozen outer surface lipoproteins that bind complement components and interfere with their native activities. Among these, BBK32 is unique in its selective inhibition of the classical pathway. BBK32 blocks activation of this pathway by selectively binding and inhibiting the C1r serine protease of the first component of complement, C1. To understand the structural basis for BBK32-mediated C1r inhibition, we performed crystallography and size-exclusion chromatography-coupled small angle X-ray scattering experiments, which revealed a molecular model of BBK32-C in complex with activated human C1r. Structure-guided site-directed mutagenesis was combined with surface plasmon resonance binding experiments and assays of complement function to validate the predicted molecular interface. Analysis of the structures shows that BBK32 inhibits activated forms of C1r by occluding substrate interaction subsites (i.e., S1 and S1') and reveals a surprising role for C1r B loop-interacting residues for full inhibitory activity of BBK32. The studies reported in this article provide for the first time (to our knowledge) a structural basis for classical pathway-specific inhibition by a human pathogen.
补体逃避是胞外微生物病原体的标志,如伯氏疏螺旋体,它是莱姆病的病原体。莱姆病螺旋体表达近十几个外表面脂蛋白,结合补体成分并干扰其天然活性。在这些脂蛋白中,BBK32 是唯一选择性抑制经典途径的。BBK32 通过选择性结合和抑制补体第一成分 C1 的 C1r 丝氨酸蛋白酶来阻断该途径的激活。为了了解 BBK32 介导的 C1r 抑制的结构基础,我们进行了晶体学和大小排阻色谱-小角 X 射线散射实验,揭示了 BBK32-C 与激活的人 C1r 复合物的分子模型。结构导向的定点突变与表面等离子体共振结合实验和补体功能测定相结合,验证了预测的分子界面。结构分析表明,BBK32 通过封闭底物相互作用亚位点(即 S1 和 S1')来抑制激活形式的 C1r,并揭示了 C1r B 环相互作用残基在 BBK32 完全抑制活性中的惊人作用。本文报道的研究首次(据我们所知)为人类病原体的经典途径特异性抑制提供了结构基础。